CNBX Pharmaceuticals Inc. (CNBX)
OTCMKTS
· Delayed Price · Currency is USD
0.0001
-0.0001 (-50.00%)
Mar 6, 2026, 4:00 PM EST
CNBX Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is September - August.
Millions USD. Fiscal year is Sep - Aug.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Nov '25 Nov 30, 2025 | Aug '25 Aug 31, 2025 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 | Aug '21 Aug 31, 2021 | 2020 - 2016 |
| Cash & Equivalents | 0.01 | 0.02 | 0.03 | 0.13 | 0.12 | 1.39 | Upgrade
|
| Cash & Short-Term Investments | 0.01 | 0.02 | 0.03 | 0.13 | 0.12 | 1.39 | Upgrade
|
| Cash Growth | -55.57% | -42.80% | -79.63% | 10.37% | -91.52% | 78.30% | Upgrade
|
| Prepaid Expenses | 0 | 0 | 0 | 0.09 | 0.08 | 0.2 | Upgrade
|
| Total Current Assets | 0.01 | 0.02 | 0.03 | 0.22 | 0.2 | 1.59 | Upgrade
|
| Property, Plant & Equipment | - | - | - | 0.27 | 0.44 | 0.64 | Upgrade
|
| Long-Term Investments | - | - | - | - | 0.18 | 0.85 | Upgrade
|
| Total Assets | 0.01 | 0.02 | 0.03 | 0.5 | 0.81 | 3.08 | Upgrade
|
| Accounts Payable | 0.05 | 0.05 | 0.04 | 0.34 | 0.46 | 0.18 | Upgrade
|
| Accrued Expenses | 1.05 | 1.04 | 0.93 | 0.61 | - | - | Upgrade
|
| Short-Term Debt | 1.25 | 1.2 | 1.3 | 1.34 | 1.76 | 0.87 | Upgrade
|
| Other Current Liabilities | 0.24 | 0.22 | 0.24 | 0.22 | 0.22 | 0.22 | Upgrade
|
| Total Current Liabilities | 2.58 | 2.51 | 2.51 | 2.52 | 2.44 | 1.27 | Upgrade
|
| Other Long-Term Liabilities | - | - | - | - | 0 | - | Upgrade
|
| Total Liabilities | 2.58 | 2.51 | 2.51 | 2.52 | 2.44 | 1.27 | Upgrade
|
| Common Stock | 0.08 | 0.06 | 0 | 0 | 0 | 0.01 | Upgrade
|
| Additional Paid-In Capital | 22.73 | 22.72 | 22.47 | 22.24 | 18.03 | 17.06 | Upgrade
|
| Retained Earnings | -25.38 | -25.27 | -24.95 | -24.26 | -20.55 | -16.83 | Upgrade
|
| Comprehensive Income & Other | - | - | - | - | 0.88 | 1.55 | Upgrade
|
| Shareholders' Equity | -2.57 | -2.5 | -2.48 | -2.02 | -1.63 | 1.81 | Upgrade
|
| Total Liabilities & Equity | 0.01 | 0.02 | 0.03 | 0.5 | 0.81 | 3.08 | Upgrade
|
| Total Debt | 1.25 | 1.2 | 1.3 | 1.34 | 1.76 | 0.87 | Upgrade
|
| Net Cash (Debt) | -1.24 | -1.18 | -1.27 | -1.21 | -1.64 | 0.51 | Upgrade
|
| Net Cash Growth | - | - | - | - | - | -33.83% | Upgrade
|
| Net Cash Per Share | -0.00 | -0.01 | -0.04 | -0.14 | -1.34 | 0.45 | Upgrade
|
| Filing Date Shares Outstanding | 870.77 | 753.2 | 31.11 | 28.31 | 1.26 | 1.24 | Upgrade
|
| Total Common Shares Outstanding | 753.2 | 553.96 | 31.11 | 22.61 | 1.26 | 1.24 | Upgrade
|
| Working Capital | -2.57 | -2.5 | -2.48 | -2.29 | -2.25 | 0.32 | Upgrade
|
| Book Value Per Share | -0.00 | -0.00 | -0.08 | -0.09 | -1.30 | 1.46 | Upgrade
|
| Tangible Book Value | -2.57 | -2.5 | -2.48 | -2.02 | -1.63 | 1.81 | Upgrade
|
| Tangible Book Value Per Share | -0.00 | -0.00 | -0.08 | -0.09 | -1.30 | 1.46 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.